It is time to include patients with brain tumors in phase I trials in oncology Journal Article


Authors: Wen, P. Y.; Schiff, D.; Cloughesy, T. F.; Reardon, D. A.; Batchelor, T. T.; Chabner, B. A.; Flaherty, K.; De Groot, J. F.; Gilbert, M. R.; Galanis, E.; Chang, S. M.; Schwartz, G. K.; Peereboom, D.; Mehta, M. P.; Yung, W. K. A.; Grossman, S. A.; Prados, M. D.; Deangelis, L. M.
Article Title: It is time to include patients with brain tumors in phase I trials in oncology
Keywords: cancer survival; drug activity; bevacizumab; drug penetration; note; drug targeting; cancer patient; rituximab; temozolomide; neurotoxicity; brain tumor; drug structure; etiracetam; topiramate; glioblastoma; blood brain barrier; drug metabolism; maximum tolerated dose; corticosteroid; life expectancy; molecular weight; lipophilicity; phenytoin; carbamazepine; harkoseride; lamotrigine; pregabalin; phase 1 clinical trial (topic)
Journal Title: Journal of Clinical Oncology
Volume: 29
Issue: 24
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2011-08-20
Start Page: 3211
End Page: 3213
Language: English
DOI: 10.1200/jco.2011.36.6328
PROVIDER: scopus
PUBMED: 21768451
PMCID: PMC4836609
DOI/URL:
Notes: --- - "Export Date: 3 October 2011" - "CODEN: JCOND" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Gary Schwartz
    385 Schwartz